Natera Q2 FY26 net loss narrows 33.65% to $67 million; revenue rises 37.7% to $752.8 million
NTRA•Updated 2026 outlook
Natera raised its 2026 revenue outlook to $2.85 billion-$2.91 billion.
CEO Steve Chapman cited regulatory wins for Signatera and expanded Medicare coverage for Prospera.
Q2 results and operating metrics
Natera posted Q2 2026 revenue of $752.8 million, up 37.7% year over year.
Net loss narrowed to $67 million, or $0.47 per share, from $100.9 million a year earlier.
Gross margin rose 1.1 percentage points to 64.5%.
Tests processed climbed 22.4% to 1,043,900; oncology tests more than doubled to 296,700.
